Pictet Asset Management
NAMS icon

Pictet Asset Management’s NewAmsterdam Pharma NAMS Stock Holding History

Pictet Asset Management’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$277K Buy
8,175
+1,642
+25% +$54.1K ﹤0.01% 1809
2026
Q1 		$209K Sell
6,533
-739,589
-99% -$24.1M ﹤0.01% 1921
2025
Q4 		$26.2M Sell
746,122
-546,028
-42% -$19.9M 0.03% 464
2025
Q3 		$36.7M Sell
1,292,150
-524,575
-29% -$12.6M 0.04% 381
2025
Q2 		$32.9M Buy
1,816,725
+4,776
+0.3% +$87.1K 0.03% 396
2025
Q1 		$37.1M Buy
1,811,949
+654,497
+57% +$14.5M 0.04% 361
2024
Q4 		$29.7M Buy
1,157,452
+140,605
+14% +$2.99M 0.03% 396
2024
Q3 		$16.9M Buy
1,016,847
+333,166
+49% +$5.76M 0.02% 535
2024
Q2 		$13.1M Buy
683,681
+33,945
+5% +$681K 0.02% 578
2024
Q1 		$15.4M Buy
+649,736
New +$13.2M 0.02% 562

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Pictet Asset Management's NAMS Position: Q2 2026 in Review

Pictet Asset Management increased its NewAmsterdam Pharma (NAMS) stake by 25% in Q2 2026, buying an estimated $54.1K and bringing the position to 8,175 shares worth $277K. The position accounts for ﹤0.01% of the portfolio, ranked #1809.

Pictet Asset Management first reported a position in NAMS in Q1 2024 and has held it in 10 quarters since. The position peaked at $37.1M in Q1 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Pictet Asset Management held 8,175 shares of NewAmsterdam Pharma worth $277K as of Q2 2026.
  • Pictet Asset Management bought 1,642 NewAmsterdam Pharma shares in Q2 2026, an estimated $54.1K.
  • NewAmsterdam Pharma made up ﹤0.01% of Pictet Asset Management's portfolio in Q2 2026, its #1809 holding.
  • Pictet Asset Management first reported a position in NewAmsterdam Pharma in Q1 2024 and has held it in 10 quarters since.
  • Pictet Asset Management's NewAmsterdam Pharma position peaked at $37.1M in Q1 2025.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.